Company*
(Country;
Symbol)

Company

Type/Product Area

Terms/Details (Date)


Amarin Corp.
plc
(UK; AMRN)

Anthony Clarke (inventor of technology)

Amarin acquired rights to an oral formulation of apomorphine for use in treating Parkinson's disease

Clarke invented the formulation prior to his hiring by Amarin; Clarke is entitled to up-front, milestone and royalty payments in the deal (5/17)

KineMed Inc.*

CMIC Co. Ltd. (Japan)

Deal under which CMIC will will seek compounds within Japanese pharmaceutical firms for potential joint development

KineMed will evaluate compounds selected by the contract research organization; it then may in-license or partner the agents; CMIC will have an option to become KineMed's partner in Japan (5/24)

Lev
Pharmaceuticals
Inc.
(OTC
BB:LEVP)

Hannu Suomela (inventor of technology)

Lev acquired exclusive rights to methods for producing plasma-derived intravenous immunoglobulin

Terms of the deal were not disclosed (5/24)

Rexahn
Pharmaceuticals
Inc.
(OTC BB:
RXHN)

Future Systems Ltd. (South Korea)

Future Systems is getting rights to three Rexahn drug candidates in certain territories

Following the deal, Rexahn would own about 28% of Future Systems, an information technology company that's expanding into the pharmaceutical business (4/24)

Symyx
Technologies
Inc.
(SMMX)

3D Systems Corp.

Deal to discover advanced materials with improved properties for use in 3D's prototyping and manufacturing solutions

3D will fund research by Symyx and will have exclusive rights to commercialize resulting materials; Symyx would get royalties on resulting sales (4/26)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.

OTC BB = Over-the-Counter Bulletin Board.

No Comments